Manipal Health IPO 2026 — SEBI Approved, Date, Price Band, GMP & Review
By ipomarket.in Editorial Team · Last reviewed: 2026-07-07
Disclaimer: This article is for informational purposes only and does not constitute investment advice. IPO investments are subject to market risks. Please read the offer document carefully and consult a SEBI-registered investment advisor before investing.
Manipal Health Enterprises Limited, India's largest hospital chain by bed count, has received SEBI approval for what is expected to be one of the largest healthcare IPOs in Indian capital market history. According to reports, the clearance covers an issue to raise nearly $1.2 billion. The fresh issue component is sized at approximately ₹8,000 crore.
Backed by Temasek (Singapore sovereign wealth fund) via TPG, and with a rapidly expanding national footprint, this IPO is being closely watched by domestic mutual funds and global healthcare investors. With the regulatory clearance now in hand, the company is reportedly targeting a public debut between late July and August 2026, though the specific open, close, and listing dates are not yet officially announced.
Manipal Health IPO — Key Details at a Glance
| Detail | Information |
|---|---|
| Company | Manipal Health Enterprises Limited |
| IPO Type | Book Build Issue |
| Fresh Issue Size | ~₹8,000 crore |
| Total Issue (reported) | ~$1.2 billion (incl. OFS) |
| Price Band | Not yet disclosed |
| Lot Size | Not yet disclosed |
| Listing Exchange | BSE and NSE |
| IPO Open Date | Not yet disclosed (target window: late July–Aug 2026) |
| IPO Close Date | Not yet disclosed |
| Lead Managers | Kotak Mahindra Capital, Axis Capital, Goldman Sachs (India), Jefferies India, J.P. Morgan India, UBS Securities India, DBS Bank India |
| Registrar | KFin Technologies |
| Status | SEBI Approved |
Price band, lot size and IPO dates will be announced after the final RHP is filed. Bookmark this page — we update it live.
What Is Manipal Health Enterprises?
Manipal Health Enterprises is the operating entity behind Manipal Hospitals, founded in 1953 in Bengaluru by Dr T.M.A. Pai. Today the chain is the largest hospital network in India by total bed count, having scaled aggressively through both organic build-out and large M&A — most notably the acquisitions of Columbia Asia Hospitals (2021), Vikram Hospital (2020), and AMRI Hospitals Kolkata (2023).
The network has expanded materially since the DRHP was filed. As of 30 September 2025, the company operated 38 hospitals with 10,761 licensed beds, which rose to 49 hospitals and 12,631 licensed beds by December 2025. Its hospitals span tertiary and quaternary care, cardiac sciences, oncology, neurosciences, transplants, and women & child health.
Ownership structure post-acquisitions (approximate):
- Temasek (TPG-routed) — ~59% stake
- Manipal Group / Pai Family — ~30%
- Other investors — ~11%
Manipal Health — Financial Performance
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue (₹ Cr) | 4,260 | 5,650 | 9,409 |
| EBITDA Margin | 24.2% | 24.1% | 26.65% |
| PAT (₹ Cr) | 280 | 470 | 720 |
Key takeaways:
- FY25 revenue of ₹9,409 crore at a 26.65% EBITDA margin reflects the full-year contribution of acquired assets and continued organic growth
- Margins held above 24% through a heavy integration phase post-AMRI acquisition
- Occupancy and ARPOB improvements continue to drive operating leverage
FY23 and FY24 figures are drawn from earlier estimates and should be reconciled against the RHP once published. FY25 revenue and margin are per recent reporting.
IPO Objective — Where Will the Money Go?
Per the DRHP, fresh issue proceeds are expected to fund:
- Debt repayment
- Greenfield expansion — new hospitals across metro and Tier-1 catchments
- Brownfield bed addition — capacity expansion at existing high-occupancy units
- General corporate purposes
The reported total issue size of around $1.2 billion suggests an offer for sale (OFS) component alongside the ₹8,000 crore fresh issue, providing a partial exit for Temasek/TPG and other early backers. The exact split is expected in the final RHP. If you are new to reading offer documents, our guide on how to read a DRHP explains what to look for.
Manipal Health — Strengths
Largest hospital chain in India: With 12,631 licensed beds as of December 2025, Manipal has greater scale than most listed peers.
Asset-light management model: A meaningful portion of the network operates under long-term O&M contracts where the real estate is owned by separate entities, which supports return on capital employed.
Strong brand equity: "Manipal" is a trusted clinical brand with 70+ years of heritage, particularly strong in South India.
Metro concentration: Hospitals in Bengaluru, Delhi NCR, Mumbai, and Kolkata sit in the highest-revenue catchments in India.
Marquee backing: Temasek has held its position through multiple cycles, signalling long-term conviction.
Healthcare tailwinds: India's hospital sector remains structurally undersupplied at roughly 1.4 beds per 1,000 people versus 3.0+ in OECD countries.
Manipal Health — Risks to Consider
Regulatory overhang: Hospital pricing is increasingly under government scrutiny. Price caps on consumables, stents, and knee implants are already in place, and future caps could compress margins.
Private equity overhang: With Temasek/TPG holding a large stake, the OFS structure and any future block sales could create persistent stock supply for several quarters post listing.
Integration risk: Rapid expansion — from 38 hospitals in September 2025 to 49 by December 2025 — brings integration challenges around culture, IT systems, and clinical protocol standardisation.
Doctor attrition: Senior consultants drive a meaningful portion of revenue. Departures can hit average revenue per occupied bed.
Insurance dependency: TPA/insurance receivables can stretch working capital and affect cash flow.
Valuation: Pricing has not been disclosed. The eventual price band relative to listed peers such as Apollo Hospitals and Max Healthcare will be the key variable for prospective investors.
Manipal Health IPO GMP (Grey Market Premium)
Grey market premium is currently unavailable because the price band has not been announced. Any GMP figure circulating before the price band is set is unreliable. GMP is an informal, unregulated indicator and not a guarantee of listing performance — see our explainer on what IPO GMP is and how it works. We will update this section here and on our live GMP tracker once the price band is out and grey market trading begins.
Manipal Health IPO — What to Watch
Manipal Health represents the largest pure-play listed hospital chain opportunity in India once it lists. The combination of scale, brand, and structural healthcare tailwinds is significant.
With SEBI approval secured, the outstanding variables are the price band and final issue structure. If the IPO is priced at a discount to listed peers, the risk-reward looks different than if it lands at parity. Prospective applicants should study the RHP financials, promoter selling in the OFS, and use-of-proceeds before forming a view.
Factors that matter for long-horizon investors:
- Belief in India's hospital underpenetration thesis
- Comfort with regulatory pricing risk in the sector
- Awareness of the PE-heavy ownership structure and potential supply overhang
This is not investment advice. Read the Red Herring Prospectus carefully before applying.
How to Apply for Manipal Health IPO
Once dates are announced, you can apply through:
- UPI-based application via Zerodha, Groww, Upstox, Paytm Money, Angel One
- ASBA via your bank's net banking
- Physical forms at designated branches
Step-by-step help is in our guide on how to apply for an IPO online in 2026. Use our IPO Allotment Checker to track allotment after the basis is finalised.
Frequently Asked Questions
Has Manipal Health IPO received SEBI approval?
Yes. According to recent reports, Manipal Health Enterprises has received SEBI approval to proceed with its IPO. Exact dates and price band still depend on the final RHP.
When will Manipal Health IPO open?
The specific open and close dates are not yet officially announced. The company is reportedly targeting a listing window of late July to August 2026, but this is guidance, not a confirmed date.
What is Manipal Health IPO size?
The fresh issue is sized at approximately ₹8,000 crore. Reports peg the total issue, including an offer for sale, at around $1.2 billion. The final split will be in the RHP.
How many hospitals does Manipal operate?
As of December 2025, Manipal operated 49 hospitals with 12,631 licensed beds, up from 38 hospitals and 10,761 beds in September 2025.
Is Manipal Health profitable?
Yes. The company reported FY25 revenue of ₹9,409 crore at a 26.65% EBITDA margin. Earlier reporting cited PAT of ₹720 crore in FY25.
Last reviewed: 7 July 2026. This article will be updated as IPO dates, price band, GMP, and allotment details are announced.